• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review - Product Image

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review

  • Published: May 2014
  • Region: Global
  • 55 pages
  • GlobalData

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- READ MORE >

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Valeant Pharmaceuticals International, Inc. - Key Facts
Valeant Pharmaceuticals International, Inc. - Key Employees
Valeant Pharmaceuticals International, Inc. - Key Employee Biographies
Valeant Pharmaceuticals International, Inc. - Major Products and Services
Valeant Pharmaceuticals International, Inc. - Pharmaceutical Pipeline Products Data
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc. - History
Valeant Pharmaceuticals International, Inc. - Company Statement
Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Valeant Pharmaceuticals International, Inc. - Key Manufacturing Facilities
Section 2 – Company Analysis
Valeant Pharmaceuticals International, Inc. - Business Description
Valeant Pharmaceuticals International, Inc. - Corporate Strategy
Valeant Pharmaceuticals International, Inc. - SWOT Analysis
SWOT Analysis - Overview
Valeant Pharmaceuticals International, Inc. - Strengths
Strength - Diversified Product Portfolio
Strength - Focus on Research & Development
Strength - Diversified Operational Presence
Valeant Pharmaceuticals International, Inc. - Weaknesses
Weakness - Legal Issues
Weakness - Dependence on Major Customers
Valeant Pharmaceuticals International, Inc. - Opportunities
Opportunity - Market Potential - Central Nervous System
Opportunity - Global Dermatology Market
Opportunity - Inorganic Growth: Strategic Acquisitions
Valeant Pharmaceuticals International, Inc. - Threats
Threat - Intense Competition
Threat - Uncertainties in R&D
Threat - Stringent Government Regulations
Valeant Pharmaceuticals International, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Valeant Pharmaceuticals International, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Valeant Pharmaceuticals International, Inc., Recent Developments
May 08, 2014: Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results
Apr 23, 2014: Valeant Pharmaceuticals Announces Nominations For Board Of Directors
Feb 27, 2014: Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
Dec 20, 2013: Valeant Pharmaceuticals To Present At Industry Conferences
Dec 13, 2013: Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance
Nov 25, 2013: Valeant Pharmaceuticals Announces New Management Appointment
Nov 15, 2013: Valeant Pharmaceuticals announces pricing of private offering of senior notes 5:01 pm
Oct 31, 2013: Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
Oct 08, 2013: Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013
Aug 07, 2013: Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Valeant Pharmaceuticals International, Inc., Key Facts
Valeant Pharmaceuticals International, Inc., Key Employees
Valeant Pharmaceuticals International, Inc., Key Employee Biographies
Valeant Pharmaceuticals International, Inc., Major Products and Services
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Development Stage
Valeant Pharmaceuticals International, Inc., Pipeline Products By Therapy Area and Development Phase
Valeant Pharmaceuticals International, Inc., History
Valeant Pharmaceuticals International, Inc., Other Locations
Valeant Pharmaceuticals International, Inc., Subsidiaries
Valeant Pharmaceuticals International, Inc., Key Manufacturing Facilities
Valeant Pharmaceuticals International, Inc., Key Competitors
Valeant Pharmaceuticals International, Inc., Ratios based on current share price
Valeant Pharmaceuticals International, Inc., Annual Ratios
Valeant Pharmaceuticals International, Inc., Interim Ratios
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Valeant Pharmaceuticals International, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc., Performance Chart (2009 - 2013)
Valeant Pharmaceuticals International, Inc., Ratio Charts
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014

Kali Laboratories, Inc.
Teva Pharmaceutical Industries Limited
Actavis, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS